Viatris' Phase 3 Trial of Pimecrolimus 0.3% (MR-139) for Blepharitis Fails to Meet Primary Endpoint

Viatris' phase 3 trial of pimecrolimus 0.3% (MR-139) for blepharitis fails to meet primary endpoint

The primary endpoint of the trial was complete resolution of debris after 6 weeks of twice daily dosing.

Viatris Fails Phase 3 Study of MR-139 for Blepharitis

Viatris announced that its phase 3 study evaluating the efficacy and safety of pimecrolimus 0.3% (MR-139) for blepharitis did not meet its primary endpoint of complete resolution of debris after six weeks of twice daily dosing. The MR-139 3001 phase 3 trial consisted of a randomized, placebo-controlled, double-masked prospective study, with a total of 477 patients who were randomized to receive either MR-139 or placebo, self-administered to the …